{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:26:09Z","timestamp":1793157969319,"version":"4.5.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,26]],"date-time":"2025-03-26T00:00:00Z","timestamp":1742947200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr. Treat. Options in Oncol."],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s11864-025-01296-7","type":"journal-article","created":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T17:04:44Z","timestamp":1743267884000},"page":"291-301","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Advances in PSMA-Targeted Radionuclide Therapeutics"],"prefix":"10.1007","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3676-2798","authenticated-orcid":false,"given":"Samuel","family":"Ruder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7374-4460","authenticated-orcid":false,"given":"Andres","family":"Ricaurte-Fajardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2907-8744","authenticated-orcid":false,"given":"Sandra","family":"Huicochea Castellanos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0232-5960","authenticated-orcid":false,"given":"Joseph R.","family":"Osborne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2777-8587","authenticated-orcid":false,"given":"Scott T.","family":"Tagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,26]]},"reference":[{"issue":"15","key":"1296_CR1","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1002\/pros.24056","volume":"80","author":"AK Miyahira","year":"2020","unstructured":"Miyahira AK, et al. Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting. Prostate. 2020;80(15):1273\u201396.","journal-title":"Prostate"},{"key":"1296_CR2","doi-asserted-by":"crossref","unstructured":"Sartor O, et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2021;385(12):1091\u2013103.","DOI":"10.1056\/NEJMoa2107322"},{"issue":"6","key":"1296_CR3","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/S1470-2045(18)30198-0","volume":"19","author":"MS Hofman","year":"2018","unstructured":"Hofman MS, et al. [(177)Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. Lancet Oncol. 2018;19(6):825\u201333.","journal-title":"Lancet Oncol"},{"key":"1296_CR4","doi-asserted-by":"crossref","unstructured":"Hofman MS, et al. [(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397(10276):797\u2013804.","DOI":"10.1016\/S0140-6736(21)00349-4"},{"key":"1296_CR5","doi-asserted-by":"crossref","unstructured":"Chi KN, et al. Safety Analyses of the Phase 3 VISION Trial of [(177)Lu]Lu-PSMA-617 in Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2024;85(4):382\u201391.","DOI":"10.1016\/j.eururo.2023.12.004"},{"key":"1296_CR6","doi-asserted-by":"crossref","unstructured":"Sartor O, Castellano Gauna DE, Herrmann K, de Bono JS, Shore ND, Chi KNN, Crosby M, Piulats JM, Flechon A, Wei XX, Mahammedi H, Roubaud G, Studentova H, Ghebremariam S, Kpamegan E, Kreisl TN, Delgoshaie N, Lehnhoff K, Morris MJ, Fizazi K. Phase 3 trial of [177Lu]Lu-PSMA-617 in taxane-naive patients with metastatic castration-resistant prostate cancer (PSMAfore). in ESMO Congress. 2023. LBA13.","DOI":"10.1016\/j.annonc.2023.10.085"},{"key":"1296_CR7","doi-asserted-by":"crossref","unstructured":"Tagawa ST et al. Preliminary results of a phase I\/II dose-escalation study of fractionated dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC). in ESMO Congress. 2019.","DOI":"10.1093\/annonc\/mdy284.008"},{"key":"1296_CR8","doi-asserted-by":"crossref","unstructured":"Eapen RS, et al. Administering [177Lu]Lu-PSMA-617 Prior to Radical Prostatectomy in Men with High-risk Localised Prostate Cancer (LuTectomy): A Single-centre, Single-arm, Phase 1\/2 Study. Eur Urol. 2024;85(3):217\u201326.","DOI":"10.1016\/j.eururo.2023.08.026"},{"issue":"13","key":"1296_CR9","doi-asserted-by":"publisher","first-page":"3595","DOI":"10.1158\/1078-0432.CCR-20-4298","volume":"27","author":"BM Priv\u00e9","year":"2021","unstructured":"Priv\u00e9 BM, et al. Lutetium-177-PSMA-617 in Low-Volume Hormone-Sensitive Metastatic Prostate Cancer: A Prospective Pilot Study. Clin Cancer Res. 2021;27(13):3595\u2013601.","journal-title":"Clin Cancer Res"},{"key":"1296_CR10","doi-asserted-by":"crossref","unstructured":"Steinhelfer L, et al. Long-Term Nephrotoxicity of (177)Lu-PSMA Radioligand Therapy. J Nucl Med. 2024;65(1):79\u201384.","DOI":"10.2967\/jnumed.123.265986"},{"issue":"10","key":"1296_CR11","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.ctrv.2015.09.001","volume":"41","author":"SC Clement","year":"2015","unstructured":"Clement SC, et al. Intermediate and long-term adverse effects of radioiodine therapy for differentiated thyroid carcinoma\u2013a systematic review. Cancer Treat Rev. 2015;41(10):925\u201334.","journal-title":"Cancer Treat Rev"},{"issue":"7","key":"1296_CR12","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1200\/JCO.2017.74.5083","volume":"36","author":"M Shadman","year":"2018","unstructured":"Shadman M, et al. Continued Excellent Outcomes in Previously Untreated Patients With Follicular Lymphoma After Treatment With CHOP Plus Rituximab or CHOP Plus 131I-Tositumomab: Long-Term Follow-Up of Phase III Randomized Study SWOG-S0016. J Clin Oncol. 2018;36(7):697\u2013703.","journal-title":"J Clin Oncol"},{"key":"1296_CR13","doi-asserted-by":"publisher","first-page":"S1185","DOI":"10.1016\/j.annonc.2022.07.1886","volume":"33","author":"AR Hansen","year":"2022","unstructured":"Hansen AR, et al. 1400P Efficacy and safety of 177Lu-PNT2002 prostate-specific membrane antigen (PSMA) therapy in metastatic castration resistant prostate cancer (mCRPC): Initial results from SPLASH. Ann Oncol. 2022;33:S1185.","journal-title":"Ann Oncol"},{"issue":"6","key":"1296_CR14","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1111\/cts.12567","volume":"11","author":"M Ovacik","year":"2018","unstructured":"Ovacik M, Lin K. Tutorial on Monoclonal Antibody Pharmacokinetics and Its Considerations in Early Development. Clin Transl Sci. 2018;11(6):540\u201352.","journal-title":"Clin Transl Sci"},{"key":"1296_CR15","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1200\/JCO.2024.42.4_suppl.161","volume":"42","author":"S Ruder","year":"2024","unstructured":"Ruder S, et al. Comparison of adverse event rate of prostate-specific membrane antigen (PSMA)-targeted radionuclide therapy (TRT) with antibody or small molecule ligand targeting vector. J Clin Oncol. 2024;42:161\u2013161.","journal-title":"J Clin Oncol"},{"issue":"18","key":"1296_CR16","doi-asserted-by":"publisher","first-page":"5182","DOI":"10.1158\/1078-0432.CCR-13-0231","volume":"19","author":"ST Tagawa","year":"2013","unstructured":"Tagawa ST, et al. Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res. 2013;19(18):5182\u201391.","journal-title":"Clin Cancer Res"},{"issue":"11","key":"1296_CR17","doi-asserted-by":"publisher","first-page":"848.e9","DOI":"10.1016\/j.urolonc.2020.05.028","volume":"38","author":"JS Batra","year":"2020","unstructured":"Batra JS, et al. Phase I trial of docetaxel plus lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 ((177)Lu-J591) for metastatic castration-resistant prostate cancer. Urol Oncol. 2020;38(11):848.e9-848.e16.","journal-title":"Urol Oncol"},{"issue":"6","key":"1296_CR18","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1634\/theoncologist.2020-0028","volume":"25","author":"MJ Niaz","year":"2020","unstructured":"Niaz MJ, et al. Pilot Study of Hyperfractionated Dosing of Lutetium-177-Labeled Antiprostate-Specific Membrane Antigen Monoclonal Antibody J591 ((177) Lu-J591) for Metastatic Castration-Resistant Prostate Cancer. Oncologist. 2020;25(6):477-e895.","journal-title":"Oncologist"},{"key":"1296_CR19","doi-asserted-by":"crossref","unstructured":"Liu RF et al. A phase 2, single-arm trial evaluating 131I-PSMA-1095 targeted radioligand therapy for metastatic castration-resistant prostate cancer. Nucl Med Commun, 2024.","DOI":"10.1097\/MNM.0000000000001858"},{"issue":"6","key":"1296_CR20","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s00259-017-3657-9","volume":"44","author":"M Sathekge","year":"2017","unstructured":"Sathekge M, et al. (213)Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2017;44(6):1099\u2013100.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"5","key":"1296_CR21","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1007\/s00259-018-4220-z","volume":"46","author":"JC dos Santos","year":"2019","unstructured":"dos Santos JC, et al. Development and dosimetry of 203Pb\/212Pb-labelled PSMA ligands: bringing \u201cthe lead\u201d into PSMA-targeted alpha therapy? Eur J Nucl Med Mol Imaging. 2019;46(5):1081\u201391.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"1296_CR22","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1056\/NEJMoa1213755","volume":"369","author":"C Parker","year":"2013","unstructured":"Parker C, et al. Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer. N Engl J Med. 2013;369(3):213\u201323.","journal-title":"N Engl J Med"},{"key":"1296_CR23","doi-asserted-by":"crossref","unstructured":"Delpassand ES et al. Abstract CT224: Preliminary efficacy and safety results from the (TATCIST) trial: A PSMA-directed targeted alpha therapy with FPI-2265 (225Ac-PSMA-I&T) for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Cancer Research, 2024. 84(7_Supplement): p. CT224-CT224.","DOI":"10.1158\/1538-7445.AM2024-CT224"},{"issue":"7","key":"1296_CR24","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1200\/JCO.23.00573","volume":"42","author":"ST Tagawa","year":"2024","unstructured":"Tagawa ST, et al. Prostate-Specific Membrane Antigen-Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of (225)Ac-J591. J Clin Oncol. 2024;42(7):842\u201351.","journal-title":"J Clin Oncol"},{"key":"1296_CR25","doi-asserted-by":"crossref","unstructured":"Nauseef JT et al. Abstract CT014: Phase I dose-escalation study of fractionated dose 225Ac J591 for metastatic castration resistant prostate cancer. Cancer Research, 2023. 83(8_Supplement): p. CT014-CT014.","DOI":"10.1158\/1538-7445.AM2023-CT014"},{"issue":"1","key":"1296_CR26","doi-asserted-by":"publisher","first-page":"62","DOI":"10.2967\/jnumed.119.229229","volume":"61","author":"M Sathekge","year":"2020","unstructured":"Sathekge M, et al. Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving 225Ac-PSMA-617 Radioligand Therapy. J Nucl Med. 2020;61(1):62\u20139.","journal-title":"J Nucl Med"},{"issue":"7","key":"1296_CR27","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1007\/s00259-023-06165-9","volume":"50","author":"M Sathekge","year":"2023","unstructured":"Sathekge M, et al. 225Ac-PSMA-617 radioligand therapy of de novo metastatic hormone-sensitive prostate carcinoma (mHSPC): preliminary clinical findings. Eur J Nucl Med Mol Imaging. 2023;50(7):2210\u20138.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1296_CR28","doi-asserted-by":"crossref","unstructured":"Higano CS et al. Clinical outcomes and treatment patterns in REASSURE: planned interim analysis of a real-world observational study of radium-223 in metastatic castration-resistant prostate cancer. eClinicalMedicine 2023. 60:101993.","DOI":"10.1016\/j.eclinm.2023.101993"},{"key":"1296_CR29","doi-asserted-by":"crossref","unstructured":"Jaggi JS et al. Mitigation of radiation nephropathy after internal \u03b1-particle irradiation of kidneys. Int J Rad Oncol Biol Phys. 2006. 64(5):1503\u20131512.","DOI":"10.1016\/j.ijrobp.2005.11.036"},{"issue":"1","key":"1296_CR30","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13550-019-0538-1","volume":"9","author":"C M\u00fcller","year":"2019","unstructured":"M\u00fcller C, et al. Preclinical investigations and first-in-human application of (152)Tb-PSMA-617 for PET\/CT imaging of prostate cancer. EJNMMI Res. 2019;9(1):68.","journal-title":"EJNMMI Res"},{"key":"1296_CR31","doi-asserted-by":"crossref","unstructured":"Al-Ibraheem A et al. 161Tb-PSMA Radioligand Therapy: First-in-human SPECT\/CT Imaging. J Nuclear Med. 2023: p. jnumed.122.265291.","DOI":"10.2967\/jnumed.122.265291"},{"key":"1296_CR32","doi-asserted-by":"crossref","unstructured":"Hammer S, et al. Preclinical Efficacy of a PSMA-Targeted Thorium-227 Conjugate (PSMA-TTC), a Targeted Alpha Therapy for Prostate Cancer. Clin Cancer Res. 2020;26(8):1985\u201396.","DOI":"10.1158\/1078-0432.CCR-19-2268"},{"issue":"2","key":"1296_CR33","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/S0090-4295(96)00184-7","volume":"48","author":"GL Wright","year":"1996","unstructured":"Wright GL, et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology. 1996;48(2):326\u201334.","journal-title":"Urology"},{"issue":"1","key":"1296_CR34","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2967\/jnumed.116.181800","volume":"58","author":"TA Hope","year":"2017","unstructured":"Hope TA, et al. 68Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human Experience. J Nucl Med. 2017;58(1):81\u20134.","journal-title":"J Nucl Med"},{"issue":"3","key":"1296_CR35","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/pros.22910","volume":"75","author":"JD Murga","year":"2015","unstructured":"Murga JD, et al. Synergistic co-targeting of prostate-specific membrane antigen and androgen receptor in prostate cancer. Prostate. 2015;75(3):242\u201354.","journal-title":"Prostate"},{"issue":"2","key":"1296_CR36","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S0360-3016(96)00513-5","volume":"37","author":"J Laverdi\u00e8re","year":"1997","unstructured":"Laverdi\u00e8re J, et al. Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer. Int J Radiat Oncol Biol Phys. 1997;37(2):247\u201352.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"1296_CR37","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/S0360-3016(97)00122-3","volume":"37","author":"AL Zietman","year":"1997","unstructured":"Zietman AL, Shipley WU. Androgen deprivation and radiation therapy in prostate cancer: the evolving case for combination therapy. Int J Radiat Oncol Biol Phys. 1997;37(2):245\u20136.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"1296_CR38","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S1470-2045(24)00135-9","volume":"25","author":"L Emmett","year":"2024","unstructured":"Emmett L, et al. [177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol. 2024;25(5):563\u201371.","journal-title":"Lancet Oncol"},{"issue":"2","key":"1296_CR39","doi-asserted-by":"publisher","first-page":"e88239","DOI":"10.1371\/journal.pone.0088239","volume":"9","author":"F Graf","year":"2014","unstructured":"Graf F, et al. DNA Double Strand Breaks as Predictor of Efficacy of the Alpha-Particle Emitter Ac-225 and the Electron Emitter Lu-177 for Somatostatin Receptor Targeted Radiotherapy. PLoS ONE. 2014;9(2):e88239.","journal-title":"PLoS ONE"},{"issue":"12","key":"1296_CR40","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1001\/jamaoncol.2022.5074","volume":"8","author":"P Loap","year":"2022","unstructured":"Loap P, et al. Concurrent Olaparib and Radiotherapy in Patients With Triple-Negative Breast Cancer: The Phase 1 Olaparib and Radiation Therapy for Triple-Negative Breast Cancer Trial. JAMA Oncol. 2022;8(12):1802\u20138.","journal-title":"JAMA Oncol"},{"issue":"4","key":"1296_CR41","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.cllc.2021.02.009","volume":"22","author":"A Argiris","year":"2021","unstructured":"Argiris A, et al. A Dose-finding Study Followed by a Phase II Randomized, Placebo-controlled Trial of Chemoradiotherapy With or Without Veliparib in Stage III Non\u2013small-cell Lung Cancer: SWOG 1206 (8811). Clin Lung Cancer. 2021;22(4):313-323.e1.","journal-title":"Clin Lung Cancer"},{"key":"1296_CR42","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1016\/j.ebiom.2018.12.060","volume":"40","author":"R Tuli","year":"2019","unstructured":"Tuli R, et al. A phase 1 study of veliparib, a PARP-1\/2 inhibitor, with gemcitabine and radiotherapy in locally advanced pancreatic cancer. EBioMedicine. 2019;40:375\u201381.","journal-title":"EBioMedicine"},{"key":"1296_CR43","doi-asserted-by":"crossref","unstructured":"Sandhu S et al. LuPARP: Phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer (mCRPC). J Clin Oncol. 2023. 41(16_suppl): 5005\u20135005.","DOI":"10.1200\/JCO.2023.41.16_suppl.5005"},{"issue":"4","key":"1296_CR44","doi-asserted-by":"publisher","first-page":"560","DOI":"10.2967\/jnumed.121.262552","volume":"63","author":"S Pathmanandavel","year":"2022","unstructured":"Pathmanandavel S, et al. (177)Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I\/II Trial. J Nucl Med. 2022;63(4):560\u20136.","journal-title":"J Nucl Med"},{"key":"1296_CR45","doi-asserted-by":"crossref","unstructured":"Tagawa ST et al. Phase I dose-escalation results of prostate-specific membrane antigen-targeted radionuclide therapy (PSMA-TRT) with alpha-radiolabeled antibody 225Ac-J591 and beta-radioligand 177Lu-PSMA I&T. J Clin Oncol. 2023. 41(16_suppl): 5018\u20135018.","DOI":"10.1200\/JCO.2023.41.16_suppl.5018"},{"key":"1296_CR46","doi-asserted-by":"crossref","unstructured":"Ruder S, Sun M, Ricaurte Fajardo A, Nauseef J, Davidson Z, Thomas J, Huicochea Castellanos S, Molina A, Sternberg C, Patel A, Fernandez E, Yuan S, Fung E, Avlonitis V, O'Dwyer E, Nanus D, Osborne J, Bander N, Tagawa S. Descriptive analysis of patients with mCRPC and liver metastases receiving alpha and beta PSMA targeted radionuclide therapy (PSMA-TRT). in AACR Annual Meeting. 2024. San Diego, CA, USA.","DOI":"10.1158\/1538-7445.AM2024-7582"},{"key":"1296_CR47","doi-asserted-by":"crossref","unstructured":"Storozynsky Q and Hitt MM. The Impact of Radiation-Induced DNA Damage on cGAS-STING-Mediated Immune Responses to Cancer. Int J Mol Sci 2020;21(22).","DOI":"10.3390\/ijms21228877"},{"issue":"1","key":"1296_CR48","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1038\/s41392-022-01102-y","volume":"7","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, et al. Radiotherapy combined with immunotherapy: the dawn of cancer treatment. Signal Transduct Target Ther. 2022;7(1):258.","journal-title":"Signal Transduct Target Ther"},{"key":"1296_CR49","doi-asserted-by":"crossref","unstructured":"Sandhu SK et al. PRINCE: Interim analysis of the phase Ib study of [177]Lu-PSMA-617 in combination with pembrolizumab for metastatic castration resistant prostate cancer (mCRPC). in ESMO Congress. 2021.","DOI":"10.1016\/j.annonc.2021.08.1090"},{"key":"1296_CR50","doi-asserted-by":"crossref","unstructured":"Sandhu S et al. PRINCE: Phase I trial of 177Lu-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology, 2022. 40(16_suppl): p. 5017\u20135017.","DOI":"10.1200\/JCO.2022.40.16_suppl.5017"},{"issue":"11","key":"1296_CR51","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1016\/S1470-2045(23)00451-5","volume":"24","author":"R Aggarwal","year":"2023","unstructured":"Aggarwal R, et al. Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial. Lancet Oncol. 2023;24(11):1266\u201376.","journal-title":"Lancet Oncol"},{"key":"1296_CR52","doi-asserted-by":"crossref","unstructured":"Sun MP et al. Phase I results of a phase I\/II study of pembrolizumab and AR signaling inhibitor (ARSI) with 225Ac-J591. J Clin Oncol. 2023. 41(6_suppl): 181\u2013181.","DOI":"10.1200\/JCO.2023.41.6_suppl.181"},{"key":"1296_CR53","doi-asserted-by":"crossref","unstructured":"Hotta M et al. Outcome of patients with PSMA-PET\/CT screen failure by VISION criteria and treated with 177Lu-PSMA therapy: a multicenter retrospective analysis. J Nuclear Med. 2022: p. jnumed.121.263441.","DOI":"10.1200\/JCO.2022.40.16_suppl.5042"},{"issue":"5","key":"1296_CR54","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1002\/pros.24104","volume":"81","author":"PJ Vlachostergios","year":"2021","unstructured":"Vlachostergios PJ, et al. Imaging expression of prostate-specific membrane antigen and response to PSMA-targeted \u03b2-emitting radionuclide therapies in metastatic castration-resistant prostate cancer. Prostate. 2021;81(5):279\u201385.","journal-title":"Prostate"},{"issue":"11","key":"1296_CR55","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/S1470-2045(22)00605-2","volume":"23","author":"JP Buteau","year":"2022","unstructured":"Buteau JP, et al. PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [(177)Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial. Lancet Oncol. 2022;23(11):1389\u201397.","journal-title":"Lancet Oncol"},{"key":"1296_CR56","doi-asserted-by":"crossref","unstructured":"Nauseef JT et al. Quantitative assessment of PSMA imaging before and after 177Lu-PSMA-617 treatment in a Ph I\/II trial. J Clin Oncol. 2022;40(6_suppl):37\u201337.","DOI":"10.1200\/JCO.2022.40.6_suppl.037"},{"key":"1296_CR57","doi-asserted-by":"crossref","unstructured":"Swiha M et al. Development of a Visually Calculated SUV(mean) (HIT Score) on Screening PSMA PET\/CT to Predict Treatment Response to (177)Lu-PSMA Therapy: Comparison with Quantitative SUV(mean) and Patient Outcomes. J Nucl Med 2024.","DOI":"10.2967\/jnumed.123.267014"},{"issue":"3","key":"1296_CR58","doi-asserted-by":"publisher","first-page":"402","DOI":"10.2967\/jnumed.122.264402","volume":"64","author":"A Karimzadeh","year":"2023","unstructured":"Karimzadeh A, et al. (177)Lu-PSMA-I&T for Treatment of Metastatic Castration-Resistant Prostate Cancer: Prognostic Value of Scintigraphic and Clinical Biomarkers. J Nucl Med. 2023;64(3):402\u20139.","journal-title":"J Nucl Med"},{"issue":"4","key":"1296_CR59","doi-asserted-by":"publisher","first-page":"517","DOI":"10.2967\/jnumed.118.219352","volume":"60","author":"J Violet","year":"2019","unstructured":"Violet J, et al. Dosimetry of 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes. J Nucl Med. 2019;60(4):517\u201323.","journal-title":"J Nucl Med"},{"issue":"2","key":"1296_CR60","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.ijrobp.2003.09.053","volume":"58","author":"A Chalmers","year":"2004","unstructured":"Chalmers A, et al. PARP-1, PARP-2, and the cellular response to low doses of ionizing radiation. Int J Radiat Oncol Biol Phys. 2004;58(2):410\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7547","key":"1296_CR61","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/nature14292","volume":"520","author":"C Twyman-Saint Victor","year":"2015","unstructured":"Twyman-Saint Victor C, et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature. 2015;520(7547):373\u20137.","journal-title":"Nature"},{"issue":"6","key":"1296_CR62","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1038\/nrclinonc.2016.211","volume":"14","author":"RR Weichselbaum","year":"2017","unstructured":"Weichselbaum RR, et al. Radiotherapy and immunotherapy: a beneficial liaison? Nat Rev Clin Oncol. 2017;14(6):365\u201379.","journal-title":"Nat Rev Clin Oncol"}],"container-title":["Current Treatment Options in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-025-01296-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11864-025-01296-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11864-025-01296-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,8]],"date-time":"2025-05-08T08:44:02Z","timestamp":1746693842000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11864-025-01296-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,26]]},"references-count":62,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["1296"],"URL":"https:\/\/doi.org\/10.1007\/s11864-025-01296-7","relation":{},"ISSN":["1527-2729","1534-6277"],"issn-type":[{"value":"1527-2729","type":"print"},{"value":"1534-6277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,26]]},"assertion":[{"value":"29 January 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2025","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In the original version of this article, the given and family names of \u201cSandra Huicochea Castellanos\u201d were incorrectly structured \u201cSandra Huicochea\u201d as GivenName, \u201cCastellanosas\u201d as FamilyName where it should have been \u201cSandra\u201d as GivenName, \u201cHuicochea Castellanos\u201d as FamilyName.","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"SR: no conflict of interest.\u00a0MS: no conflict of interest. ARF: no conflict of interest.\u00a0SHC: no conflict of interest.\u00a0JRO: consulting or advisory role: Medscape, UroToday, Siemens Healthineer. Travel, acommodations, expenses: Siemens HealthineersSTT: institutional fees from AbbVie, Ambrx, Amgen, Astellas, AstraZeneca, Aveo, Bayer, Bristol Myers Squibb, Clarity, Clovis, Endocyte, Genentech, Gilead, Inovio, Janssen, Karyopharm, Medivation, Merck, Newlink, Novartis, POINT Biopharma, Rexahn, Sanofi, and Seattle Genetics; and consultant fees from AbbVie, Aikido Pharma, Ambrx, Amgen, Astellas, Bayer, Blue Earth, Clarity Pharma, Clovis, Convergent Therapeutics, Daiichi Sankyo, Eisai, EMD Serono, Genentech, Genomic Health, Janssen, Medivation, Merck, Myovant, Novartis, Pfizer, POINT Biopharma, Regeneron, Sanofi, Seattle Genetics, Telix, Tolmar, and TransThera.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}